Health Economics›Hepatoblastoma›All lines of therapy

All lines of therapy

Hepatoblastoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cisplatin and Doxorubicin N/A - secondary systemic drug	—	R 3 077	21d	~5.7 mo	~12.3 mo	~9	~R 27 693 PFS proxy · indirect	4
Cisplatin monotherapy Variant #16	—	R 650	28d	~2.1 mo	~8.7 mo	~3	~R 1 950 PFS proxy · indirect	8

2 of 2 regimens shown